Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI)

Olivier Pradier, Margret Rave-Fränk, Jörg Lehmann, Eva Lücke, Oliver Boghun, Clemens F. Hess, Heinz Schmidberger

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The purpose of this study was to determine, as we did for paclitaxel, the cytotoxic and radiosensitizing potential of docetaxel in human head and neck cancer cells (ZMK-I), and in cervical squamous cell carcinoma cells (CaSki). ZMK-I cells were incubated with docetaxel for 3, 9 or 24 hr before irradiation and 24 hr after irradiation. CaSki cells were incubated with docetaxel 24 hr before and after irradiation. For ZMK-I cells, the docetaxel concentrations (0.7, 0.7 and 0.35 nM) were determined to obtain approximately equivalent cell survival at the different incubation times (3, 9 and 24 hr, respectively). For CaSki cells, the necessary concentration of docetaxel was 0.07 nM. Radiation doses were given from 0 to 7 Gy. Cell survival was measured by a standard clonogenic assay after a 9-day incubation. Flow cytometry was used to measure the capacity of docetaxel to accumulate cells in the G2/M phase of the cell cycle. We observed a weak accumulation of cells in the G2/M phase for the ZMK-I cells and a pronounced accumulation for CaSki cells. For docetaxel incubation before irradiation, the isoeffect enhancement ratios for ZMK-I cells determined at the 37% survival level were 1.18, 2.01, and 2.40 for pre-incubation at 3, 9 and 24 hr, respectively; for CaSki cells the ratio was 1.44. For a docetaxel incubation of 24 hr after irradiation, the isoeffect enhancement ratios determined at the 37% survival level were 1.54 and 1.17 for the ZMK-I, and CaSki cells, respectively. A radiosensitizing effect of docetaxel could be demonstrated unambiguously in the two cell lines used. In contrast to our previously published results with paclitaxel, docetaxel seems to be a better radiosensitizer than paclitaxel.

Original languageEnglish (US)
Pages (from-to)840-845
Number of pages6
JournalInternational Journal of Cancer
Volume91
Issue number6
DOIs
StatePublished - Mar 15 2001
Externally publishedYes

Fingerprint

docetaxel
Head and Neck Neoplasms
Squamous Cell Carcinoma
Radiation
Paclitaxel
G2 Phase
Cell Division
Cell Survival

Keywords

  • Docetaxel
  • Radiosensitisation
  • Radiotherapy
  • SCC-cell lines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI). / Pradier, Olivier; Rave-Fränk, Margret; Lehmann, Jörg; Lücke, Eva; Boghun, Oliver; Hess, Clemens F.; Schmidberger, Heinz.

In: International Journal of Cancer, Vol. 91, No. 6, 15.03.2001, p. 840-845.

Research output: Contribution to journalArticle

Pradier, Olivier ; Rave-Fränk, Margret ; Lehmann, Jörg ; Lücke, Eva ; Boghun, Oliver ; Hess, Clemens F. ; Schmidberger, Heinz. / Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI). In: International Journal of Cancer. 2001 ; Vol. 91, No. 6. pp. 840-845.
@article{666310d64a7c4eeeb8dfc07955187712,
title = "Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI)",
abstract = "The purpose of this study was to determine, as we did for paclitaxel, the cytotoxic and radiosensitizing potential of docetaxel in human head and neck cancer cells (ZMK-I), and in cervical squamous cell carcinoma cells (CaSki). ZMK-I cells were incubated with docetaxel for 3, 9 or 24 hr before irradiation and 24 hr after irradiation. CaSki cells were incubated with docetaxel 24 hr before and after irradiation. For ZMK-I cells, the docetaxel concentrations (0.7, 0.7 and 0.35 nM) were determined to obtain approximately equivalent cell survival at the different incubation times (3, 9 and 24 hr, respectively). For CaSki cells, the necessary concentration of docetaxel was 0.07 nM. Radiation doses were given from 0 to 7 Gy. Cell survival was measured by a standard clonogenic assay after a 9-day incubation. Flow cytometry was used to measure the capacity of docetaxel to accumulate cells in the G2/M phase of the cell cycle. We observed a weak accumulation of cells in the G2/M phase for the ZMK-I cells and a pronounced accumulation for CaSki cells. For docetaxel incubation before irradiation, the isoeffect enhancement ratios for ZMK-I cells determined at the 37{\%} survival level were 1.18, 2.01, and 2.40 for pre-incubation at 3, 9 and 24 hr, respectively; for CaSki cells the ratio was 1.44. For a docetaxel incubation of 24 hr after irradiation, the isoeffect enhancement ratios determined at the 37{\%} survival level were 1.54 and 1.17 for the ZMK-I, and CaSki cells, respectively. A radiosensitizing effect of docetaxel could be demonstrated unambiguously in the two cell lines used. In contrast to our previously published results with paclitaxel, docetaxel seems to be a better radiosensitizer than paclitaxel.",
keywords = "Docetaxel, Radiosensitisation, Radiotherapy, SCC-cell lines",
author = "Olivier Pradier and Margret Rave-Fr{\"a}nk and J{\"o}rg Lehmann and Eva L{\"u}cke and Oliver Boghun and Hess, {Clemens F.} and Heinz Schmidberger",
year = "2001",
month = "3",
day = "15",
doi = "10.1002/1097-0215(200002)9999:9999<::AID-IJC1142>3.0.CO;2-U",
language = "English (US)",
volume = "91",
pages = "840--845",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI)

AU - Pradier, Olivier

AU - Rave-Fränk, Margret

AU - Lehmann, Jörg

AU - Lücke, Eva

AU - Boghun, Oliver

AU - Hess, Clemens F.

AU - Schmidberger, Heinz

PY - 2001/3/15

Y1 - 2001/3/15

N2 - The purpose of this study was to determine, as we did for paclitaxel, the cytotoxic and radiosensitizing potential of docetaxel in human head and neck cancer cells (ZMK-I), and in cervical squamous cell carcinoma cells (CaSki). ZMK-I cells were incubated with docetaxel for 3, 9 or 24 hr before irradiation and 24 hr after irradiation. CaSki cells were incubated with docetaxel 24 hr before and after irradiation. For ZMK-I cells, the docetaxel concentrations (0.7, 0.7 and 0.35 nM) were determined to obtain approximately equivalent cell survival at the different incubation times (3, 9 and 24 hr, respectively). For CaSki cells, the necessary concentration of docetaxel was 0.07 nM. Radiation doses were given from 0 to 7 Gy. Cell survival was measured by a standard clonogenic assay after a 9-day incubation. Flow cytometry was used to measure the capacity of docetaxel to accumulate cells in the G2/M phase of the cell cycle. We observed a weak accumulation of cells in the G2/M phase for the ZMK-I cells and a pronounced accumulation for CaSki cells. For docetaxel incubation before irradiation, the isoeffect enhancement ratios for ZMK-I cells determined at the 37% survival level were 1.18, 2.01, and 2.40 for pre-incubation at 3, 9 and 24 hr, respectively; for CaSki cells the ratio was 1.44. For a docetaxel incubation of 24 hr after irradiation, the isoeffect enhancement ratios determined at the 37% survival level were 1.54 and 1.17 for the ZMK-I, and CaSki cells, respectively. A radiosensitizing effect of docetaxel could be demonstrated unambiguously in the two cell lines used. In contrast to our previously published results with paclitaxel, docetaxel seems to be a better radiosensitizer than paclitaxel.

AB - The purpose of this study was to determine, as we did for paclitaxel, the cytotoxic and radiosensitizing potential of docetaxel in human head and neck cancer cells (ZMK-I), and in cervical squamous cell carcinoma cells (CaSki). ZMK-I cells were incubated with docetaxel for 3, 9 or 24 hr before irradiation and 24 hr after irradiation. CaSki cells were incubated with docetaxel 24 hr before and after irradiation. For ZMK-I cells, the docetaxel concentrations (0.7, 0.7 and 0.35 nM) were determined to obtain approximately equivalent cell survival at the different incubation times (3, 9 and 24 hr, respectively). For CaSki cells, the necessary concentration of docetaxel was 0.07 nM. Radiation doses were given from 0 to 7 Gy. Cell survival was measured by a standard clonogenic assay after a 9-day incubation. Flow cytometry was used to measure the capacity of docetaxel to accumulate cells in the G2/M phase of the cell cycle. We observed a weak accumulation of cells in the G2/M phase for the ZMK-I cells and a pronounced accumulation for CaSki cells. For docetaxel incubation before irradiation, the isoeffect enhancement ratios for ZMK-I cells determined at the 37% survival level were 1.18, 2.01, and 2.40 for pre-incubation at 3, 9 and 24 hr, respectively; for CaSki cells the ratio was 1.44. For a docetaxel incubation of 24 hr after irradiation, the isoeffect enhancement ratios determined at the 37% survival level were 1.54 and 1.17 for the ZMK-I, and CaSki cells, respectively. A radiosensitizing effect of docetaxel could be demonstrated unambiguously in the two cell lines used. In contrast to our previously published results with paclitaxel, docetaxel seems to be a better radiosensitizer than paclitaxel.

KW - Docetaxel

KW - Radiosensitisation

KW - Radiotherapy

KW - SCC-cell lines

UR - http://www.scopus.com/inward/record.url?scp=0035869657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035869657&partnerID=8YFLogxK

U2 - 10.1002/1097-0215(200002)9999:9999<::AID-IJC1142>3.0.CO;2-U

DO - 10.1002/1097-0215(200002)9999:9999<::AID-IJC1142>3.0.CO;2-U

M3 - Article

C2 - 11275989

AN - SCOPUS:0035869657

VL - 91

SP - 840

EP - 845

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -